Pulmonx Corporation - Common Stock (LUNG)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Mar 31, 2026Investment Snapshot
- P/B of 0.92 — trading below book value
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -106.7%
- Revenue growing at 8% annually
Pulmonx Corporation - Common Stock (LUNG) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $50 million . Key value metrics: P/B ratio 0.92, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Pulmonx Corporation - Common Stock — Fundamental Analysis Summary
On financial health, LUNG shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -106.7% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.69.
StockPik's composite Value Score for LUNG is 65/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
LUNG reports a high gross margin of 73.2% (sector average: 33.5%) and a negative operating margin of -65.6%.
LUNG shows revenue growing at 8% year-over-year, with earnings growing at 4%.